Geron Corporation (FRA:GON)
Germany · Delayed Price · Currency is EUR | Market Cap | 644.60M -11.2% |
| Revenue (ttm) | 170.09M +68.6% |
| Net Income | -58.38M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,109 |
| Open | 1.000 |
| Previous Close | 1.053 |
| Day's Range | 1.000 - 1.030 |
| 52-Week Range | 0.915 - 1.628 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Geron
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clini... [Read more]
Financial Performance
In 2025, Geron's revenue was $183.88 million, an increase of 138.83% compared to the previous year's $76.99 million. Losses were -$83.50 million, -52.17% less than in 2024.
Financial numbers in USD Financial StatementsNews
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, tod...
Geron Transcript: AGM 2026
The meeting approved all board proposals, including director elections and incentive plan changes. Updates highlighted progress in clinical trials, organizational restructuring, and plans for ex-U.S. commercialization, with key trial results expected by 2028.
Geron Transcript: Stifel 2026 Targeted Oncology Virtual Forum
RYTELO's commercial rollout is accelerating, with updated NCCN guidelines supporting second-line use and strong uptake in community settings. Real-world and long-term data reinforce efficacy and safety, while financial guidance points to near-term profitability and strategic optionality.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock opti...
Geron Transcript: Bank of America Global Healthcare Conference 2026
RYTELO continues to gain traction in low-risk MDS, with strong Q1 revenue and expanding use in the second-line setting. Real-world evidence supports clinical trial results, and an interim readout for imetelstat in myelofibrosis is expected later this year.
Geron to present RWE study of RYTELO at EHA Congress
Geron (GERN) Corporation announced that the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes will be presented at the European Hematology Association 202...
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
Geron reports Q1 EPS (1c), consensus (2c)
Reports Q1 revenue $51.84M, consensus $50.59M. “We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to exe...
Geron Earnings Call Transcript: Q1 2026
Q1 2026 saw 31% year-over-year revenue growth and disciplined expense management, keeping the company on track for its 2026 guidance. U.S. RYTELO demand rose 6% sequentially, with commercial and medical strategies fueling further growth and European expansion plans underway.
Geron Earnings release: Q1 2026
Geron released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Geron Quarterly report: Q1 2026
Geron has published its Q1 2026 quarterly earnings report on May 6, 2026.
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating exp...
Geron Slides: Corporate presentation
Geron has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Geron Plans to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, toda...
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to...
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a ...
Geron Transcript: 25th Annual Needham Virtual Healthcare Conference
Imetelstat, a first-in-class telomerase inhibitor, is driving growth in low-risk MDS with $184M revenue in 2025 and guidance of $220–$240M for 2026. Focus is on expanding second-line use, physician education, and advancing a pivotal myelofibrosis trial.
Geron appoints Timothy Williams as chief legal officer
Geron (GERN) announced the appointment of Timothy Williams as executive VP, chief legal officer and corporate secretary. Tim Williams served as senior VP, general counsel and Secretary at Vanda Pharma...
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial ...
Geron Proxy statement: Proxy filing
Geron filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Geron Proxy statement: Proxy filing
Geron filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, to...
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos a...
Geron Transcript: Barclays 28th Annual Global Healthcare Conference
RYTELO achieved strong initial sales and is positioned for 20–30% growth in 2026, driven by second-line MDS market expansion and a focus on community adoption. The drug's unique mechanism and positive long-term data support confidence in further uptake, while a pivotal MF trial could unlock additional value.
Geron Transcript: TD Cowen 46th Annual Health Care Conference
RYTELO achieved $184 million in first-year sales, with 2025 guidance of $220–$240 million, driven by strategic focus on second-line MDS patients and refined commercial execution. EMA approval and ongoing ISTs support international expansion and broader clinical applications.